These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

878 related articles for article (PubMed ID: 29236052)

  • 1. microRNAs in Parkinson's Disease: From Pathogenesis to Novel Diagnostic and Therapeutic Approaches.
    Leggio L; Vivarelli S; L'Episcopo F; Tirolo C; Caniglia S; Testa N; Marchetti B; Iraci N
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29236052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The deglycase activity of DJ-1 mitigates α-synuclein glycation and aggregation in dopaminergic cells: Role of oxidative stress mediated downregulation of DJ-1 in Parkinson's disease.
    Sharma N; Rao SP; Kalivendi SV
    Free Radic Biol Med; 2019 May; 135():28-37. PubMed ID: 30796974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease.
    Büeler H
    Exp Neurol; 2009 Aug; 218(2):235-46. PubMed ID: 19303005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cell biology of Parkinson's disease.
    Panicker N; Ge P; Dawson VL; Dawson TM
    J Cell Biol; 2021 Apr; 220(4):. PubMed ID: 33749710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The regulatory role of α-synuclein and parkin in neuronal cell apoptosis; possible implications for the pathogenesis of Parkinson's disease.
    Yasuda T; Mochizuki H
    Apoptosis; 2010 Nov; 15(11):1312-21. PubMed ID: 20221696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNAs in Parkinson's disease.
    Mouradian MM
    Neurobiol Dis; 2012 May; 46(2):279-84. PubMed ID: 22245218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parkinson's disease and alpha-synucleinopathies: from arising pathways to therapeutic challenge.
    Miraglia F; Betti L; Palego L; Giannaccini G
    Cent Nerv Syst Agents Med Chem; 2015; 15(2):109-16. PubMed ID: 25896035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of recent genetic findings in Parkinson's disease.
    Klein C; Lohmann-Hedrich K
    Curr Opin Neurol; 2007 Aug; 20(4):453-64. PubMed ID: 17620882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microglia and astrocyte dysfunction in parkinson's disease.
    Kam TI; Hinkle JT; Dawson TM; Dawson VL
    Neurobiol Dis; 2020 Oct; 144():105028. PubMed ID: 32736085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding multifactorial architecture of Parkinson's disease: pathophysiology to management.
    Kaur R; Mehan S; Singh S
    Neurol Sci; 2019 Jan; 40(1):13-23. PubMed ID: 30267336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives.
    Sarkar S; Raymick J; Imam S
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27338353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Potential Roles of Extracellular Vesicles as Biomarkers for Parkinson's Disease: A Systematic Review.
    Valencia J; Ferreira M; Merino-Torres JF; Marcilla A; Soriano JM
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apoptosis in Parkinson's disease: is p53 the missing link between genetic and sporadic Parkinsonism?
    Alves da Costa C; Checler F
    Cell Signal; 2011 Jun; 23(6):963-8. PubMed ID: 20969953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
    Olanow CW; Brundin P
    Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysregulated microRNAs in neural system: Implication in pathogenesis and biomarker development in Parkinson's disease.
    Lu J; Xu Y; Quan Z; Chen Z; Sun Z; Qing H
    Neuroscience; 2017 Dec; 365():70-82. PubMed ID: 28964753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers of Parkinson's disease: present and future.
    Miller DB; O'Callaghan JP
    Metabolism; 2015 Mar; 64(3 Suppl 1):S40-6. PubMed ID: 25510818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parkinson's disease.
    Thomas B; Beal MF
    Hum Mol Genet; 2007 Oct; 16 Spec No. 2():R183-94. PubMed ID: 17911161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genes, proteins, and neurotoxins involved in Parkinson's disease.
    von Bohlen und Halbach O; Schober A; Krieglstein K
    Prog Neurobiol; 2004 Jun; 73(3):151-77. PubMed ID: 15236834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interplay between α-synuclein and parkin genes: Insights of Parkinson's disease.
    Sharma K; Chib S; Gupta A; Singh R; Chalotra R
    Mol Biol Rep; 2024 Apr; 51(1):586. PubMed ID: 38683365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural genomic variations and Parkinson's disease.
    Bandrés-Ciga S; Ruz C; Barrero FJ; Escamilla-Sevilla F; Pelegrina J; Vives F; Duran R
    Minerva Med; 2017 Oct; 108(5):438-447. PubMed ID: 28541025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.